Physician profile
Christopher A Sheppard
NPI 1306924964
$175,438.65
in general payments reported to CMS, 2019-2025
31 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $28K · 2021: $28K · 2022: $2,211 · 2023: $2,626 · 2024: $2,142 · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,597 · Consulting Fee: $475 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $10.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,596.89 |
| Consulting Fee | $475.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $10.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69,271.21 | 2019-2025 | |
| Genentech USA, INC. | $23,777.60 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Emd Serono, INC. | $22,706.01 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $15,901.52 | 2019-2025 | |
| Celgene Corporation | $13,266.34 | 2019-2025 | Zeposia |
| Biogen, INC. | $9,563.00 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Mallinckrodt Enterprises LLC | $7,071.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $6,754.82 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $2,442.38 | 2020-2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $1,483.64 | 2019-2025 | Ultomiris, Soliris |
| Banner Life Sciences, LLC | $917.08 | 2020-2023 | |
| Tg Therapeutics, INC. | $842.20 | 2022-2025 | |
| Genentech, INC. | $231.06 | 2019-2025 | Ocrevus |
| Janssen Pharmaceuticals, INC | $176.64 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $166.99 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $121.95 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $105.43 | 2022-2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $82.41 | 2023-2024 | Nuedexta |
| Horizon Therapeutics Plc | $79.50 | 2022-2023 | Uplizna |
| Axsome Therapeutics, INC. | $74.26 | 2023-2024 | Sunosi |
| Amgen INC. | $69.08 | 2024-2025 | Uplizna |
| Cycle Pharmaceuticals INC | $68.80 | 2024-2025 | Tascenso Odt, Bafiertam |
| Acorda Therapeutics, INC | $67.39 | 2022-2024 | Ampyra, Inbrija |
| Vanda Pharmaceuticals INC. | $50.04 | 2025 | Ponvory |
| Mylan Specialty L.P. | $35.54 | 2022-2024 | Glatiramer Acetate |
| Sandoz INC. | $34.18 | 2024 | |
| Validus Pharmaceuticals LLC | $21.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.20 | 2019 | |
| Sumitomo Pharma America, INC. | $15.62 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.